Catalog No. |
TD-VK539036 |
Description |
Libivirumab is a human monoclonal antibody directed against the hepatitis B virus. Libivirumab had an IC50 of 35 and 128 ng/ml in the neutralization assays based on ELISA and immunofluorescence assays. |
Species reactivity |
Hepatitis B virus genotype A (HBV-A) |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
IgG1, kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
Large envelope protein, L glycoprotein, L-HBsAg, LHB, Large S protein, Large surface protein, Major surface antigen, S |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P03142 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
17.1.41,HepeX-B(combinationofexbivirumabandlibivirumab),CAS:569658-79-3 |
Background |
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |